Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 2/20 | 0.47 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.45 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.44 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.42 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.42 |
| ▸ | HINT1 | P49773 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13396546 | 0.88 | P2RY2 (0.56) | P2RY1P2RY2P2RY11P2RX1P2RX3 | |
| SCHEMBL13396544 | 0.88 | NT5E (0.49) | NT5EIMPDH2IMPDH1HINT1CA5A | |
| SCHEMBL3319958 | 0.88 | NT5E (0.49) | NT5EIMPDH2IMPDH1HINT1CA5A | |
| SCHEMBL3319967 | 0.88 | NT5E (0.49) | NT5EIMPDH2IMPDH1HINT1CA5A | |
| SCHEMBL13396541 | 0.85 | POLB (0.53) | NT5EP2RY2P2RY6 | |
| SCHEMBL14150113 | 0.84 | NT5E (0.44) | NT5EP2RY1ENPP1P2RY12P2RY2 | |
| SCHEMBL13396774 | 0.83 | P2RY2 (0.35) | NT5EP2RY1ENPP1P2RY12P2RY2 | |
| SCHEMBL12932296 | 0.80 | P2RY1 (0.58) | NT5EP2RY1ENPP1P2RY12P2RY2 | |
| SCHEMBL15703855 | 0.80 | P2RY1 (0.58) | NT5EP2RY1ENPP1P2RY12P2RY2 | |
| SCHEMBL14102502 | 0.79 | NT5E (0.40) | NT5EHINT1CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | NT5E 226/4885P2RY1 505/4885ENPP1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.